US Senator Arlen Specter Diagnosed With Hodgkins
Senator Arlen Specter, R-Pa., announced Wednesday that he has Hodgkin's disease. Specter had experienced persistent fevers and enlarged lymph nodes under his left arm and above his left clavicle. He received testing on February 14th at Thomas Jefferson University Hospital. The testing involved biopsy of a lymph node and biopsy of bone marrow. The lymph node was positive for Hodgkin’s disease. The bone marrow biopsy showed no cancer. A follow up PET scan and MRI at the Abramson Cancer Center of the University of Pennsylvania on February 16th established that Senator Specter has stage IVB Hodgkin’s disease.
Senator Specter is expected to receive ABVD chemotherapy every two weeks over the next 24 to 32 weeks at the Abramson Cancer Center.
"I have beaten a brain tumor, bypass heart surgery and many tough political opponents and I'm going to beat this, too," Specter said in a statement. He expects to continue to work in the Senate while being treated
Press Release from Senator Specter's office
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
